• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

管理糖尿病合并急性冠状动脉综合征患者的住院高血糖症和起始钠-葡萄糖共转运蛋白 2 抑制剂治疗。

Managing inpatient hyperglycaemia and initiating sodium-glucose cotransporter 2 inhibitor therapy in the setting of diabetes and acute coronary syndrome.

机构信息

Department of Endocrinology and Diabetes, Fiona Stanley Hospital, Perth, Western Australia, Australia.

Department of Pharmacy, Fiona Stanley Hospital, Perth, Western Australia, Australia.

出版信息

Intern Med J. 2021 Mar;51(3):428-432. doi: 10.1111/imj.15245.

DOI:10.1111/imj.15245
PMID:33738945
Abstract

We previously showed that implementing algorithms for managing diabetes in acute coronary syndrome was associated with improved inpatient glycaemic control and increased sodium-glucose cotransporter 2 (SGLT2) inhibitor prescriptions. The present study performed 1 year later found that inpatient hyperglycaemia had relapsed to pre-intervention rates, although SGLT2 inhibitor prescriptions remained increased. We discuss the challenges of improving inpatient glycaemic control.

摘要

我们之前曾表明,实施急性冠状动脉综合征患者的糖尿病管理算法与改善住院期间血糖控制和增加钠-葡萄糖共转运蛋白 2(SGLT2)抑制剂的处方有关。本研究在 1 年后进行,发现住院期间的高血糖已恢复到干预前的水平,尽管 SGLT2 抑制剂的处方仍在增加。我们讨论了改善住院期间血糖控制的挑战。

相似文献

1
Managing inpatient hyperglycaemia and initiating sodium-glucose cotransporter 2 inhibitor therapy in the setting of diabetes and acute coronary syndrome.管理糖尿病合并急性冠状动脉综合征患者的住院高血糖症和起始钠-葡萄糖共转运蛋白 2 抑制剂治疗。
Intern Med J. 2021 Mar;51(3):428-432. doi: 10.1111/imj.15245.
2
Implementing simple algorithms to improve glucose and lipid management in people with diabetes and acute coronary syndrome.实施简单算法以改善糖尿病合并急性冠状动脉综合征患者的血糖和血脂管理。
Diabet Med. 2019 Dec;36(12):1643-1651. doi: 10.1111/dme.14095. Epub 2019 Aug 9.
3
Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.钠-葡萄糖共转运蛋白抑制剂:治疗 2 型糖尿病的治疗潜力。
Diabetes Metab Res Rev. 2013 Jul;29(5):347-56. doi: 10.1002/dmrr.2403.
4
Real-world evaluation of glucose-lowering therapies and the use of weight-adjusted variable rate intravenous insulin infusion in the management of hyperglycaemia in patients with acute coronary syndrome (REGULATE-ACS).急性冠状动脉综合征患者高血糖管理中降糖治疗的真实世界评估及体重调整的可变速率静脉胰岛素输注的应用(REGULATE-ACS研究)
Int J Cardiol. 2023 Jan 1;370:26-34. doi: 10.1016/j.ijcard.2022.10.158. Epub 2022 Oct 29.
5
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.钠-葡萄糖协同转运蛋白2与二肽基肽酶-4抑制作用:一对充满潜力的组合
Endocr Pract. 2017 Jul;23(7):831-840. doi: 10.4158/EP161725.RA. Epub 2017 Mar 23.
6
Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.钠-葡萄糖协同转运蛋白2选择性抑制剂依帕列净对链脲佐菌素诱导的1型糖尿病大鼠高血糖、氧化应激、炎症及肝损伤的影响
J Pharm Pharmacol. 2014 Jul;66(7):975-87. doi: 10.1111/jphp.12223. Epub 2014 Feb 17.
7
SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus.SGLT2 抑制剂:治疗 2 型糖尿病的有前途的新治疗选择。
J Pharm Pharmacol. 2013 Mar;65(3):317-27. doi: 10.1111/j.2042-7158.2012.01574.x. Epub 2012 Aug 9.
8
Comparison between SGLT2 inhibitors and DPP4 inhibitors added to insulin therapy in type 2 diabetes: a systematic review with indirect comparison meta-analysis.在2型糖尿病胰岛素治疗中添加钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂与二肽基肽酶4(DPP4)抑制剂的比较:一项采用间接比较荟萃分析的系统评价
Diabetes Metab Res Rev. 2017 Jan;33(1). doi: 10.1002/dmrr.2818. Epub 2016 Jun 8.
9
Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.2型糖尿病中使用钠-葡萄糖协同转运蛋白2抑制剂治疗高血糖的实际考量
Curr Med Res Opin. 2016 Jun;32(6):1097-108. doi: 10.1185/03007995.2016.1161608. Epub 2016 Apr 4.
10
Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.SGLT2 选择性抑制剂伊格列净对 2 型糖尿病小鼠高血糖、高血脂、肝脂肪变性、氧化应激、炎症和肥胖的影响。
Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. doi: 10.1016/j.ejphar.2013.05.014. Epub 2013 May 23.

引用本文的文献

1
Learnings from Implementation Strategies to Improve Lipid Management.从改善血脂管理的实施策略中获得的经验教训。
Curr Cardiol Rep. 2025 Jan 8;27(1):9. doi: 10.1007/s11886-024-02174-8.
2
The Diagnostic Value of Combined Detection of Serum Lp-PLA2 and Hcy and Color Doppler in Elderly Patients with Acute Coronary Syndrome and Effect on Endothelial Function.血清Lp-PLA2与同型半胱氨酸联合检测及彩色多普勒对老年急性冠状动脉综合征患者的诊断价值及其对内皮功能的影响
Evid Based Complement Alternat Med. 2022 Jul 8;2022:3150670. doi: 10.1155/2022/3150670. eCollection 2022.